OPKO IP Holdings II, Inc. clinical trials

Acquired by OPKO Health, Inc., Mar 4, 2013 · source ↗

The registry lists 5 studies whose lead sponsor is OPKO IP Holdings II, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 13, 2025.

Before and after it joined OPKO Health, Inc.

First submitted before OPKO IP Holdings II, Inc. became part of OPKO Health, Inc.: 5
First submitted after OPKO IP Holdings II, Inc. became part of OPKO Health, Inc.: 0
Unclear, or no submission date: 0

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

Status

Completed: 5

Phase

Phase 1: 2
Phase 3: 2
Phase 2: 1

Where

United States: 5
Canada: 1

Registry sponsor names on this page

OPKO IP Holdings II, Inc.5 studies

Something wrong with this grouping? Tell us on the OPKO Health, Inc. page.

Studies

Recruiting first, then most recently updated. Showing 5 of 5. All OPKO Health, Inc. studies →

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCompletedNCT01651000Phase 3
Sponsor listed in the registry: OPKO IP Holdings II, Inc. · First submitted before OPKO IP Holdings II, Inc. became part of OPKO Health, Inc.
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCompletedNCT01704079Phase 3
Sponsor listed in the registry: OPKO IP Holdings II, Inc. · First submitted before OPKO IP Holdings II, Inc. became part of OPKO Health, Inc.
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney DiseaseCompletedNCT00742716Phase 2
Sponsor listed in the registry: OPKO IP Holdings II, Inc. · First submitted before OPKO IP Holdings II, Inc. became part of OPKO Health, Inc.
Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease SubjectsCompletedNCT00888069Phase 1
Sponsor listed in the registry: OPKO IP Holdings II, Inc. · First submitted before OPKO IP Holdings II, Inc. became part of OPKO Health, Inc.
Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)CompletedNCT00792857Phase 1
Sponsor listed in the registry: OPKO IP Holdings II, Inc. · First submitted before OPKO IP Holdings II, Inc. became part of OPKO Health, Inc.